Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667479 | 0.96 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL668492 | 0.94 | AGTR1 (0.44) | AGTR1AGTR2PPARG | |
| SCHEMBL668512 | 0.90 | AGTR1 (0.44) | AGTR1AGTR2PPARG | |
| SCHEMBL668484 | 0.90 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL668741 | 0.86 | AGTR1 (0.44) | AGTR1AGTR2PPARG | |
| SCHEMBL3849928 | 0.85 | AGTR1 (0.49) | AGTR1AGTR2PPARG | |
| SCHEMBL668713 | 0.84 | AGTR1 (0.49) | AGTR1AGTR2PPARG | |
| SCHEMBL667462 | 0.83 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL7878781 | 0.82 | AGTR1 (0.36) | AGTR1AGTR2PPARG | |
| SCHEMBL7878405 | 0.82 | AGTR1 (0.36) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | OSAKA UNIVERSITY (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885PPARG 428/4885 |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | SOST, CD14, MYD88 | AGTR1 35/4885AGTR2 64/4885PPARG 850/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885PPARG 1211/4885 |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | AGTR1, AGTR2, MC2R | AGTR1 1/4885AGTR2 2/4885PPARG 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.